4.1 Review

Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care

出版社

TAYLOR & FRANCIS LTD
DOI: 10.3109/13651501.2012.667114

关键词

Anxiety disorders; guidelines; panic disorder; generalized anxiety disorder; social anxiety disorder; pharmacological treatment

资金

  1. AstraZeneca
  2. Bristol-Myers-Squibb
  3. Glaxo-SmithKline
  4. Jazz
  5. Merck
  6. Lilly
  7. Lundbeck
  8. Ono Pharma
  9. Otsuka
  10. Pfizer
  11. Servier
  12. Teva
  13. Abbott BMS
  14. Janssen
  15. Nastech
  16. Neuropharm
  17. Wyeth
  18. Bristol-Myers Squibb
  19. CSC
  20. Eli Lilly
  21. Janssen Pharmaceutica
  22. MSD
  23. Novartis
  24. Organon
  25. Pierre Fabre
  26. Schwabe
  27. Sepracor
  28. Janssen Cilag

向作者/读者索取更多资源

Objective. Anxiety disorders are frequently under-diagnosed conditions in primary care, although they can be managed effectively by general practitioners. Methods. This paper is a short and practical summary of the World Federation of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder (OCD) and posttraumatic stress disorder (PTSD) for the treatment in primary care. The recommendations were developed by a task force of 30 international experts in the field and are based on randomized controlled studies. Results. First-line pharmacological treatments for these disorders are selective serotonin reuptake inhibitors (for all disorders), serotonin-norepinephrine reuptake inhibitors (for some) and pregabalin (for generalized anxiety disorder only). A combination of medication and cognitive behavior/exposure therapy was shown to be a clinically desired treatment strategy. Conclusions. This short version of an evidence-based guideline may improve treatment of anxiety disorders, OCD, and PTSD in primary care.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据